PURPOSE: To report tumor local progression-free outcomes after treatment with single-dose, image-guided, intensity-modulated radiotherapy and hypofractionated regimens for extracranial metastases from renal cell primary tumors. PATIENTS AND METHODS: Between 2004 and 2010, 105 lesions from renal cell carcinoma were treated with either single-dose, image-guided, intensity-modulated radiotherapy to a prescription dose of 18-24 Gy (median, 24) or hypofractionation (three or five fractions) with a prescription dose of 20-30 Gy. The median follow-up was 12 months (range, 1-48). RESULTS: The overall 3-year actuarial local progression-free survival for all lesions was 44%. The 3-year local progression-free survival for those who received a high single-dose (24 Gy; n = 45), a low single-dose (<24 Gy; n = 14), or hypofractionation regimens (n = 46) was 88%, 21%, and 17%, respectively (high single dose vs. low single dose, p = .001; high single dose vs. hypofractionation, p < .001). Multivariate analysis revealed the following variables were significant predictors of improved local progression-free survival: 24 Gy dose compared with a lower dose (p = .009) and a single dose vs. hypofractionation (p = .008). CONCLUSION: High single-dose, image-guided, intensity-modulated radiotherapy is a noninvasive procedure resulting in high probability of local tumor control for metastatic renal cell cancer generally considered radioresistant according to the classic radiobiologic ranking. Copyright Â
PURPOSE: To report tumor local progression-free outcomes after treatment with single-dose, image-guided, intensity-modulated radiotherapy and hypofractionated regimens for extracranial metastases from renal cell primary tumors. PATIENTS AND METHODS: Between 2004 and 2010, 105 lesions from renal cell carcinoma were treated with either single-dose, image-guided, intensity-modulated radiotherapy to a prescription dose of 18-24 Gy (median, 24) or hypofractionation (three or five fractions) with a prescription dose of 20-30 Gy. The median follow-up was 12 months (range, 1-48). RESULTS: The overall 3-year actuarial local progression-free survival for all lesions was 44%. The 3-year local progression-free survival for those who received a high single-dose (24 Gy; n = 45), a low single-dose (<24 Gy; n = 14), or hypofractionation regimens (n = 46) was 88%, 21%, and 17%, respectively (high single dose vs. low single dose, p = .001; high single dose vs. hypofractionation, p < .001). Multivariate analysis revealed the following variables were significant predictors of improved local progression-free survival: 24 Gy dose compared with a lower dose (p = .009) and a single dose vs. hypofractionation (p = .008). CONCLUSION: High single-dose, image-guided, intensity-modulated radiotherapy is a noninvasive procedure resulting in high probability of local tumor control for metastatic renal cell cancer generally considered radioresistant according to the classic radiobiologic ranking. Copyright Â
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Yoshiya Yamada; Mark H Bilsky; D Michael Lovelock; Ennapadam S Venkatraman; Sean Toner; Jared Johnson; Joan Zatcky; Michael J Zelefsky; Zvi Fuks Journal: Int J Radiat Oncol Biol Phys Date: 2008-01-30 Impact factor: 7.038
Authors: Toni K Choueiri; Mei Sheng Duh; Jessica Clement; Ashley J Brick; Miranda J Rogers; Christabel Kwabi; Karishma Shah; Andrew G Percy; Lucia Antràs; Sujata S Jayawant; Kristina Chen; Si-Tien Wang; Andi Luka; Maureen P Neary; David McDermott; William K Oh Journal: BJU Int Date: 2009-10-26 Impact factor: 5.588
Authors: Zhouguang Hui; Maria Tretiakova; Zhongfa Zhang; Yan Li; Xiaozhen Wang; Julie Xiaohong Zhu; Yuanhong Gao; Weiyuan Mai; Kyle Furge; Chao-Nan Qian; Robert Amato; E Brian Butler; Bin Tean Teh; Bin S Teh Journal: Int J Radiat Oncol Biol Phys Date: 2009-01-01 Impact factor: 7.038
Authors: Peter S Rose; Ilya Laufer; Patrick J Boland; Andrew Hanover; Mark H Bilsky; Josh Yamada; Eric Lis Journal: J Clin Oncol Date: 2009-09-08 Impact factor: 44.544
Authors: Shankar Siva; Gargi Kothari; Alexander Muacevic; Alexander V Louie; Ben J Slotman; Bin S Teh; Simon S Lo Journal: Nat Rev Urol Date: 2017-06-20 Impact factor: 14.432
Authors: Yoshiya Yamada; Evangelia Katsoulakis; Ilya Laufer; Michael Lovelock; Ori Barzilai; Lily A McLaughlin; Zhigang Zhang; Adam M Schmitt; Daniel S Higginson; Eric Lis; Michael J Zelefsky; James Mechalakos; Mark H Bilsky Journal: Neurosurg Focus Date: 2017-01 Impact factor: 4.047
Authors: M Protopapa; V Kouloulias; A Kougioumtzopoulou; Z Liakouli; C Papadimitriou; A Zygogianni Journal: Clin Transl Oncol Date: 2019-06-28 Impact factor: 3.405
Authors: Sahra Bodo; Cécile Campagne; Tin Htwe Thin; Daniel S Higginson; H Alberto Vargas; Guoqiang Hua; John D Fuller; Ellen Ackerstaff; James Russell; Zhigang Zhang; Stefan Klingler; HyungJoon Cho; Matthew G Kaag; Yousef Mazaheri; Andreas Rimner; Katia Manova-Todorova; Boris Epel; Joan Zatcky; Cristian R Cleary; Shyam S Rao; Yoshiya Yamada; Michael J Zelefsky; Howard J Halpern; Jason A Koutcher; Carlos Cordon-Cardo; Carlo Greco; Adriana Haimovitz-Friedman; Evis Sala; Simon N Powell; Richard Kolesnick; Zvi Fuks Journal: J Clin Invest Date: 2019-01-14 Impact factor: 14.808
Authors: F A Calvo; C V Sole; R Martinez-Monge; I Azinovic; J Aristu; J Zudaire; J L Garcia-Sabrido; J M Berian Journal: Strahlenther Onkol Date: 2012-12-09 Impact factor: 3.621